Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa ... the function of retinal cells.

It is focusing on retinal diseases, with its most advanced programme AGTC-501 for X-linked retinitis pigmentosa (XLRP), which is in the phase 2/3 VISTA trial. AGTC-501 is vying to become the first ...

ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to ...

In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ...

Explore how biotech breakthroughs in 2024 have changed lives, bringing real Christmas miracles to patients and offering hope ...

Tim Newberry, Antoinette Nez and their 9-year-old son will spend this Christmas together for the first time under the same ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

Victorian researchers are a step closer to treating and reversing ‘incurable’ blindness using groundbreaking gene therapy ...

作为一档旨在聚集医疗健康领域重要产业趋势与发展洞见、定期分享红杉中国医疗成员企业特写文章与最新动态的栏目，2024年《Healthcare View》共记录了70余家红杉中国医疗成员企业累计上百件重要新闻。这些新闻既是企业发展的见证，也是行业脉动的映射。